High Quality Vitamin a Acid/ Tretinoin CAS 302-79-4 Retinoic Acid

• Customization: Available
• Grade: USP42
• CAS: 302-79-4
• Model NO.: py0019
• Molecular Formula: C20h27o2
• Ec No.: 206-129-0
• Purity: 99%Min
• Transport Package: Drum
• Specification: 25kg/drum
• Trademark: puya
• Origin: China
• HS Code: 2923900091
• Production Capacity: 5ton/Year

Product Description

Product Name: Retinoic acid
Synonyms: Tretinoin Retinoic acid in stock Factory;Isotretinoin Impurity 1sotretinoin EP Impurity A TRETINOIN;TRETINOIN VITAMIN A ACID;TRANS-RETINOIC ACID;TRANS VITAMIN A ACID;Retinoic acid NanoEmulsion, Liposomal Retinoic acid, Water-Soluble Retinoic acid;VITAMIN A ACID
CAS: 302-79-4
MF: C20H28O2
MW: 300.44
EINECS: 206-129-0
Melting point: 180-181ºC(lit.)
Boiling point: 381.66ºC (rough estimate)
Density: 1.0597 (rough estimate)
Storage temp.: 2-8ºC
Appearance: Yellow to light-orange crystalline powder
Solubility: Practically insoluble in water, soluble in methylene
chloride, slightly soluble in ethanol (96 per cent).


Tretinoin is available in 10-mg capsules for oral administrationin the treatment of APL. The mechanism of action involvespassive diffusion through the cell membrane andthen movement to the nucleus where it interacts with theretinoic acid receptor (RAR) portion of the PML-RAR fusionprotein. Binding of tretinoin allows the cell to differentiateand has also been shown to result in the destruction ofthe PML-RAR fusion protein. Resistance to tretinoin isproblematic and associated with an increase in cellularretinoic acidinding proteins (CRAPBs) located in the cytosol.The complexation with tretinoin prevents movementinto the nucleus and may present the drug to metabolizingenzymes that inactivate it. Amino acid mutation of thePML-RAR protein has also been established as a mechanismof resistance. The agent is well absorbed upon oral administrationand highly (95%) protein bound. Metabolismoccurs in the liver and several inactive metabolites havebeen identified including 13-cis-retinoic acid, 4-oxo cisretinoic,4-oxo trans-retinoic acid and 4-oxo trans-retinoicacid glucuronide. Elimination occurs in the urine (63%) andfeces (31%) with an elimination half-life of 40 to 120 minutes.Vitamin A toxicity is seen in nearly all patients andpresents as headache, fever, dryness of the skin, skin rash,mucositis, and peripheral edema. APL differentiation syndromesuch as that seen for trioxide also occurs.Cardiovascular effects include flushing, hypotension, CHF,stroke, and myocardial infarction have been reported butoccur only rarely. There are also several CNS and GI effectsthat have been associated with the agent as well.

Uses:

(1) Applies to abnormal tyshiyongyupe of acne, fish phosphorus disease and abnormal psoriasis.
(2) Resistance to abnormal skin drugs.
(3) Tretinoin mainly affects the growth of bones and epithelial metabolism, can promote epithelial cell proliferation and updates, and can inhibit the proliferation and differentiation of keratinocytes, so hyperkeratosis can be back to normal. Therefore many complete or incomplete keratosis, hyperkeratosis of diseases have a certain therapeutic effect, treat a variety of skin diseases. Tretinoin is mainly used in the treatment of psoriasis, ichthyosis, follicular keratosis, acne, lichen planus, verrucous epidermal nevus, impetigo, vitiligo, lichen psoriasis, the face of pityriasis alba, etc.

Usage Dosage:

(1) ointment: use 0.1% ointment for the other skin lesions and 0.05% ointment for acne skin lesions in the topical application. Clean the skin with warm water after one time every night.
(2) gel: apply to the affected area. At the beginning of treatment , it can be taken one time every two days or every three days. Afterwards smear one time every night.

Application Area:
1. Tretinoin is widely applied in pharmaceutical field, mainly used for the cure of dermatonosus like acne, ichthyosis and psoriasis abnormal, etc..
2.Tretinoin can be made into tretinoin or retinoic acid cream to cureacne or other unhealthy skin.
3.Tretinoin is used for skin keratinocytes-resistant drugs and cell-induced differentation drug.